Method Development Insights

Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table

Method development is the first real moment of truth in a bioanalytical project. It sets the trajectory for everything that follows, from validation to sample analysis to final reporting.

And yet, one of the most common challenges we see is not technical. It is alignment.

Strong method development does not start in the lab. It starts with what the sponsor brings into the conversation.

Why This Matters 

A well-developed method is not just about sensitivity or selectivity. It is about fitness for purpose.

If the foundation is unclear, teams end up iterating, reworking, and losing time. In early development programs, that time matters.

The difference between a smooth program and a reactive one often comes down to the quality of inputs at the start.

What Sponsors Should Provide Upfront 

1. Clear Study Objectives

What decisions will this data support? This sounds simple, but it drives everything:

• required sensitivity (LLOQ)
• dynamic range
• turnaround expectations
• regulatory expectations

Without this, method development becomes guesswork.

2. Molecule Understanding

Basic characterization is critical:

• structure and class (small molecule, peptide, ADC, etc.)
• solubility
• known metabolites or expected biotransformations
• stability profile (if known)

Any previous observations helps the lab anticipate challenges early.

3. Matrix and Species Strategy

Where will this method be applied?

• preclinical species vs. clinical
• plasma, serum, tissue, or microsamples
• special populations or conditions

Matrix drives complexity. Tissue and microsampling require very different approaches than standard plasma work.

4. Expected Concentration Ranges

Even rough estimates are valuable:

• C_max expectations
• anticipated PK profile
• dose levels

This informs assay range and avoids rework when real samples arrive.

5. Reference Materials and Standards

Availability and quality matter:

• certificate of analysis
  • purity
  • storage conditions
• API standards
• internal standards
• metabolite standards (if applicable)

Delays here can stall development entirely.

6. Regulatory Context

Is this:

• exploratory
• GLP toxicology
• clinical (GCP-aligned)

The level of rigor and documentation changes based on intended use.

7. Timeline and Priorities

Be explicit:

• key milestones
• critical path studies
• flexibility vs. fixed deadlines

This helps labs allocate resources appropriately and avoid surprises.

Where Things Break Down 

Most issues we see are not capability gaps. They are communication gaps.

• assumptions about expected sample concentrations
• late changes in matrix or species
• misalignment on regulatory expectations

These lead to avoidable delays and rework.

Best Practice: Treat Method Development as a Partnership 

The most successful programs share a common approach:

• early, direct communication with scientific teams
• transparent discussion of risks and unknowns
• willingness to align on “fit-for-purpose” vs. “perfect”

Method development is not a transactional step. It is a strategic one.

Final Thought 

If you want speed, quality, and reliability downstream, invest the time upfront. The best bioanalytical methods are not just developed. They are built on clarity.

Looking for more information on method development?

Download the “Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table” Infographic
View this infographic for seven key elements sponsors should provide at the start of method development.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Method Development Expectations: Where Programs Quietly Go Off Track

Method development rarely fails because of technical limitations. It fails because expectations were never clearly defined.

And the issue often starts early, even if it is not recognized until much later.

At Alturas, we consistently see that misalignment at this stage does not stop progress. It redirects it.

Why This Matters

When expectations are unclear, teams keep moving. But they move in the wrong direction.

Time is spent optimizing performance that may not be required. Complexity is introduced without purpose. And what should be structured iteration becomes reactive troubleshooting.

We recently saw a program where an aggressive LLOQ target was set without a clear link to study decisions. The result was weeks of added development time with no impact on the outcome of the study.

In early-stage programs, that time matters.

What Needs to Be Defined Early

1. Fit-for-Purpose Performance: The key decision at this stage is simple: What does the method actually need to do? Define required sensitivity, acceptable variability, and the decisions the data must support. Without this, teams default to building toward an undefined 'best case.'
2. The Role of Iteration: Method development is inherently iterative across extraction, chromatography, and detection. Iteration is not inefficiency; it is the process.
3. Trade-Offs Must Be Explicit: Every method balances sensitivity, robustness, and throughput. In one program, aligning early that robustness mattered more than absolute sensitivity reduced complexity and accelerated delivery.
4. Timeline vs. Complexity: Faster timelines always come with trade-offs. The decision is what can be relaxed to move faster.

Where Things Break Down

• validation-level expectations applied too early
• sensitivity targets pushed beyond study needs
• matrix complexity underestimated
• timelines compressed without defined trade-offs

Best Practice: Align Before You Optimize

At Alturas, we approach method development as a decision-making phase, not just execution.

Define success early, align on trade-offs, and accept iteration as part of the process.

Final Thought

If method development feels unpredictable, it is rarely the science. It is the absence of clearly defined expectations.

Clarity does not eliminate iteration. It makes iteration productive.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Method Development: Where You Start Determines Where You End Up

Most method development challenges do not come from complexity. They come from where the process starts.

Too often, method development begins at the instrument instead of at the problem.

Why This Matters

Starting in the wrong place compounds inefficiency. Teams waste time optimizing parameters before confirming method objectives.

Where Method Development Should Start

1. Understand the Molecule: Structure, solubility, stability, and expected metabolites are key to developing the assay efficiently.
2. Define the Matrix: Plasma vs. tissue vs. microsamples introduce different biological challenges that need to be overcome during method development.
3. Confirm Detection Feasibility: Can the analyte be detected with acceptable signal-to-noise and selectivity at the desired LLOQ?
4. Start Simple: Begin with straightforward extraction (e.g., protein precipitation) and add complexity only when required.

Where Things Break Down

• jumping straight to instrumentation and extraction
• not researching the molecule
• reinventing previous methods that worked
• underestimating matrix impact

Best Practice: Build, Don’t Guess

At Alturas, we start with fundamentals, confirm feasibility early, and build complexity only when needed.

Final Thought

Where you start determines how efficient method development becomes. Start with the problem, not the instrument.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Avoiding the Pitfalls of Method Development Before They Cost You Time

Most method development problems are not surprises.

They are predictable.

The issue is not that they occur. It is when they are identified.

Why This Matters

Late-stage issues are expensive to fix.

Repeating experiments to address these issues can cost your program extra time and money.

Common Pitfalls

1. Over-Optimization Too Early — Refining performance before confirming objectives decreases efficiency.
2. Late Identification of Matrix Effects — Co-elution and ion suppression must be evaluated early.
3. Stability Assumptions — Unverified stability can invalidate data and force revalidation.
4. Chasing Unnecessary Sensitivity — Lower LLOQ is not always better; it often adds complexity and results in unnecessary sample dilution.

Where Things Break Down

• matrix effects and stability not assessed
• optimization without clear objectives

Best Practice: Identify Risk Early

At Alturas, we prioritize simplest extraction possible, matrix effects evaluation and matrix stability checks to prevent downstream rework.

Final Thought

The fastest programs are not the ones that fix problems quickly.

They are the ones that prevent them.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Method Transfer Is Where Bioanalytical Methods Quietly Fail

Most transferred methods do not break during initial development. They break when assumptions meet a new laboratory environment.

Transferred methods should always be critically reviewed prior to implementation in the receiving laboratory. It is crucial to determine whether the method is built on good bioanalytical fundamentals or if it is standing on poor decisions and inefficient techniques.

A method that was validated in one laboratory is not automatically ready for seamless execution in another. 

• different LC systems
• different mass spectrometers
• different analysts
• different extraction workflows
• different sample handling conditions
• different columns, reagents, and robotics

Small differences can create significant variability causing accuracy and precision problems with the method.

This is where we consistently see bioanalytical programs quietly lose time, create rework, and introduce unnecessary risk.

Method transfer is not an administrative handoff. It is a scientific reassessment of robustness, reproducibility, and fitness-for-purpose under new operating conditions.

As a CRO, we often see transferred methods arrive with assumptions from our clients that need to be challenged:

• recovery is consistent
• matrix effects remain controlled
• stability is consistent between different laboratory environments
• sensitivity requirements are met
• instrument and extraction parameters were fully optimized
• critical method variables were clearly defined in the method

Sometimes they do.

Sometimes they do not.

And the cost of discovering those gaps late compounds the complexity of the method development impacting validation timelines and sample analysis.

The strongest transfers happen when sponsors and CRO teams approach the process collaboratively and scientifically from the beginning.

That means aligning early on: 

• method intent and study objectives
• critical performance characteristics
• historical challenges and known limitations
• instrumentation and platform differences
• sample handling expectations
• risk areas before validation or study execution begins

Strong method transfer is not about proving the original method worked.

It is about proving the method remains reliable, reproducible, and defensible in the new laboratory environment where critical study decisions and regulatory data generation occur.

That difference matters more than most teams realize.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Study Samples Stress Method Development Diligence

Study samples expose assay weaknesses that can’t be tested in method development using purchased matrices spiked with the target compound.

This is where otherwise promising bioanalytical methods begin to struggle.

• analytical variability increases
• sample matrix consistency isn’t uniform
• sample handling conditions change
• unpredictable stability challenges emerge

And what looked robust during method development suddenly becomes far more complex under real study conditions.

As a CRO, we see this most often when methods are developed around idealized assumptions instead of operational reality.

Study samples introduce variables that cannot be ignored:

• biological variability
• complex or changing matrices
• collection and handling inconsistencies
• low sample volumes
• stability risks during processing and storage
• unexpected concentration distributions

The strongest bioanalytical methods are not designed only for analytical performance.

They are designed for real-world execution.

That means considering how the method will behave across the actual study lifecycle, not just under controlled development conditions.

Because once study samples arrive, the cost of discovering gaps increases quickly.

Strong sample bioanalysis starts long before the first sample is analyzed.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

Mass Spec Optimization Isn't About Sensitivity.
It's About Selectivity.

One of the most common misconceptions in bioanalytical method development is that a better assay is simply a more sensitive assay.

In reality, many of the most difficult bioanalytical challenges are solved by improving selectivity, not by chasing lower LLOQs.

When a method struggles during development, the root cause is often one of three issues:

• Matrix interferences generating false signal
• Poor fragmentation efficiency limiting quantitative transitions
• Ion suppression that cannot be resolved through sample preparation alone

The temptation is often to continue optimizing extraction or chromatography. Sometimes the bigger opportunity is to revisit the mass spectrometer itself.

Questions we routinely evaluate during development include:

• Is the correct precursor ion selected based on the target molecular weight?
• Are the selected product ions the most selective transitions available?
• Based on the structure, what is the best ionization mode and polarity?
• Are source conditions maximizing analyte response while minimizing matrix effects?
• Is the signal to noise greater than 10 at the projected LLOQ?

In complex matrices, small changes in source parameters, collision energies, dwell times, or transition selection can significantly improve assay performance and robustness.

The result isn't simply a lower LLOQ.

The result is a method that performs consistently when it reaches validation and, ultimately, sample analysis.

What is the most challenging mass spectrometry optimization issue you've encountered during method development: sensitivity, selectivity, or matrix effects?

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

LC Optimization: The Most Undervalued Step in Bioanalytical Method Development

Everyone wants better mass spectrometry. Few ask if the chromatography is the problem.

When a bioanalytical method struggles during development, the first instinct is often to focus on the mass spectrometer.

Can we improve ionization?

Can we identify a better transition?

Can we increase sensitivity?

Can we optimize source parameters?

These are important questions. But in many cases, the real bottleneck isn't the mass spectrometer at all.

It's the chromatography.

One of the most common observations we see during method development is an overemphasis on MS optimization before the liquid chromatography has been optimized.

The result is often a method that performs adequately during development but struggles when exposed to the variability of study samples.

Why LC Optimization Matters

Liquid chromatography isn’t just a runway to get the analyte to the mass spectrometer.

It directly impacts:

• Selectivity
• Matrix interference removal
• Ion suppression mitigation
• Peak shape
• Quantitation reproducibility
• Method robustness
• Long-term assay performance

A mass spectrometer can only analyze what reaches the source.

Poor chromatography creates problems that no amount of mass spectrometry optimization can fully overcome.

The Hidden Cost of Inadequate Chromatographic Resolution

One of the most overlooked development risks occurs when co-eluting matrix components remain unresolved resulting in ion suppression or inaccurate quantitation.

The method may appear acceptable when evaluated using neat standards or limited matrix lots. However, once the assay encounters diverse study samples containing the dose excipients, previously hidden interferences begin to emerge.

Common consequences include:

• Elevated baseline noise
• Variable ion suppression
• Inconsistent analyte response
• Increased assay variability
• Unexpected selectivity failures

These issues frequently become apparent much later in development—sometimes during validation or even during sample analysis.

At that stage, corrective actions become significantly more expensive and time consuming.

What We Evaluate During LC Optimization

Successful LC optimization requires a systematic approach.

Questions often include:

• Have alternative column chemistries been evaluated?
• Is retention adequate to separate analyte from matrix components?
• Are peak shapes symmetrical and reproducible with minimal fronting or tailing?
• Is gradient design maximizing separation without unnecessarily extending run time and sacrificing peak shape?
• Have mobile phase additives been optimized for both chromatography and ionization performance?
• Has carryover been mitigated appropriately?
• Is the method robust across multiple matrix lots?

Optimization is rarely about a single variable.

It is about understanding how the entire chromatographic system behaves under realistic analytical conditions.

Selectivity Often Outperforms Sensitivity

A common misconception is that assay performance is primarily determined by sensitivity.

In reality, improved selectivity often delivers greater gains than incremental improvements in signal intensity.

A cleaner chromatographic separation can:

• Reduce background noise
• Improve signal-to-noise ratios
• Enhance reproducibility
• Reduce matrix effects
• Tighten up assay accuracy and precision
• Ultimately improve confidence in reported concentrations

Good chromatography will always produces better quantitative performance than simply applying a more sensitive detector setting.

Developing for Validation, Not Demonstration

One of the goals of method development is not simply to generate a chromatogram that works.

The goal is to create a method that remains reliable throughout validation and routine sample analysis.

The question should never be:

"Can this chromatographic setup work?"

The more important question is:

"Will this chromatographic setup still work after hundreds of injections, multiple analysts, multiple matrices, and months of study support?"

That mindset often changes how LC optimization is approached.

Final Thought

Mass spectrometry frequently receives most of the attention during bioanalytical method development. Yet chromatography is often where method robustness is won or lost.

The most successful assays are rarely the product of a single optimization step.

They result from thoughtful integration of sample preparation, chromatography, and mass spectrometry into a system that performs reliably under real-world conditions. Because ultimately, the best assay is not the one that produces the largest signal.

It's the one that consistently produces the right answer.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.

When a Method Fails During Sample Analysis,
Is It Really the Method? 

One of the most expensive mistakes in bioanalytical method development is assuming that poor assay performance automatically means the method requires further optimization.

Sometimes it does.

Often, it doesn't.

Experienced scientists know that method development can become a seemingly endless cycle of chromatography adjustments, extraction modifications, mass spec parameter optimization and additional validation experiments. Yet despite significant effort, performance remains inconsistent.

The question worth asking is:

Are you solving a method problem, or are you trying to compensate for a study design, sample, or analyte problem?

The Hidden Causes of Method Development Failure

When an assay struggles, the investigation frequently focuses on analytical variables:

• Poor reproducibility at LLOQ
• Extraction recovery
• Inconsistent chromatographic peak shape
• Matrix effects
• Internal standard variability
• MS tuning parameters

These are all appropriate places to start.

However, many difficult development programs ultimately trace back to factors outside the analytical method itself. Examples include:

Analyte Instability

The method may perform exceptionally well on freshly prepared standards while showing significant variability in study samples or day-to-day batch preparation.

In these situations, degradation can occur:

• During collection
• During processing
• During storage
• Through repeated freeze-thaw cycles

No amount of instrument optimization will recover analyte that is no longer present.

Sample Collection Artifacts

Unexpected variability is often attributed to assay precision.

Yet variability can originate upstream through:

• Inconsistent collection techniques
• Delayed plasma separation
• Improper anticoagulant selection
• Sample handling differences across sites

These issues frequently appear as method performance problems like incurred sample reanalysis failures because they manifest during sample analysis.

Biology Mistaken for Analytical Variability

One of the most challenging situations occurs when biological variability is interpreted as analytical variability.

Questions worth asking include:

• Is the analyte highly protein bound or unevenly partitioned in the red blood cells?
• Are metabolites contributing to ion suppression or enhancement?
• Is target-mediated disposition creating unexpected concentration behavior?
• Are disease-state effects altering matrix composition?

Without understanding the biology, method optimization efforts can become increasingly disconnected from the true source of variability.

Reference Standard Issues

Another overlooked source of development challenges involves reference materials themselves.

Questions we routinely evaluate include:

• Is the reference material fully characterized?
• Has purity been independently confirmed?
• Is the standard representative of the analyte present in study samples?
• Is the analyte and internal standard soluble in the chosen solvent?
• Are stock/working solutions stable throughout the development and validation period?

A highly optimized assay built around a poorly characterized reference standard can create months of downstream troubleshooting.

Questions We Ask Before Re-Optimizing a Method

Before making significant method changes, we often step back and ask:

• Has analyte stability been fully characterized?
• Have collection and handling procedures been challenged?
• Does observed variability exceed expected biological variability?
• Has reference standard integrity been confirmed?
• Are matrix effects being driven by study-specific biology rather than analytical conditions?
• Are we solving the correct problem?

The final question is often the most important.

The Best Method Development Teams Think Beyond the Method

Strong method development is not simply analytical optimization.

It is scientific investigation.

The most successful development programs occur when scientists are willing to challenge the assumption that the method itself is the root cause.

Sometimes the assay needs optimization.

Sometimes the real answer is hidden somewhere upstream.

The ability to distinguish between those two scenarios is often what separates a straightforward development program from months of unnecessary troubleshooting.

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.